Sareum Holdings Progresses SDC-1801 with New Toxicology Studies Ahead of Phase 2 Trials

PUBLISHED: 29 May 2025 @ 18:19 | Comments (0) | More info about Fiona Craig

Sareum Holdings (LSE:SAR) has launched toxicology studies for its lead TYK2/JAK1 inhibitor, SDC-1801, marking a crucial milestone on the path toward Phase 2 clinical trials targeting psoriasis. These studies, which are required for regulatory clearance, are scheduled for completion by the fourth quarter of 2025. This effort aligns with Sareum’s broader goal of advancing its autoimmune drug pipeline, building on encouraging Phase 1 trial results.

While Sareum continues to face financial challenges due to a lack of revenue and ongoing losses—factors that negatively impact its overall evaluation—the company’s recent scientific progress and positive corporate developments offer a degree of optimism. Technical signals indicate some near-term strength, though valuation concerns persist because of negative earnings.

About Sareum Holdings

Sareum Holdings PLC is a Cambridge-based biotech firm specializing in the development of innovative kinase inhibitors for autoimmune diseases and oncology. Its portfolio includes small molecule drugs targeting the JAK kinase family, with lead candidates SDC-1801 and SDC-1802 focusing on TYK2 and JAK1. Additionally, Sareum is developing SRA737, a Checkpoint kinase 1 inhibitor designed for cancer therapy.

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.